September 18, 2013
Genomma Lab is targeting September 25 for the sale of up to MXP2.0bn ($154m
Genomma Lab is targeting September 25 for the sale of up to MXP2.0bn ($154m) in domestic bonds, according to people familiar with the deal. The Mexican pharmaceutical and hygiene products company is planning 4-year fixed-rate notes. Proceeds will be used for general corporate purposes. Banamex and Santander are managing the new deal, rated AA on a national scale. In July, Genomma Lab sold a MXP2bn 5-year floating-rate bond at TIIE+70bp, getting MXP3.15bn in orders.